Effects of sodium-glucose cotransport-2 inhibitors treatment in patients with pulmonary hypertension
Background: Pulmonary hypertension (PH) is a complex disorder associated with various underlying conditions, including cardiac and respiratory diseases. PH is classified into five groups based on etiology, disease mechanisms, hemodynamic data, and treatment options. Preliminary data suggest that sod...
Saved in:
Main Authors: | Mohammed Obeidat, Aravinthan Vignarajah, Rashid Abdel-Razeq, Ala’eddien Nathir, Nishanthi A. Vigneswaramoorthy, Adriano R. Tonelli |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-06-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/17534666251351443 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01) -
Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01) -
Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01) -
Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01) -
Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor
by: D. A. Lebedev, et al.
Published: (2020-10-01)